PDI expects reduction in AstraZeneca field reps; backs out of upcoming conference

By E. Janene Geiss

Philadelphia, Feb. 10 - PDI, Inc. said Friday that it is engaged in discussions with AstraZeneca regarding the status of their fee-for-service contract sales engagements.

PDI currently has about 800 field representatives under contract with AstraZeneca, according to a company news release.

PDI said it expects there will be significant reductions to the number of representatives contracted with AstraZeneca and will comment further once it has more definitive information regarding the scope and timing of the anticipated changes.

PDI also said that due to these recent developments, it will not be presenting at the upcoming UBS Global Healthcare Services Conference in New York City as previously planned.

PDI, based in Saddle River, N.J., is a diversified sales and marketing services provider to the biopharmaceutical industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.